mTOR inhibition in glioblastoma: requiem for a dream?

Affiliations

Comment

Sam Babak et al. Neuro Oncol. 2018.

. 2018 Apr 9;20(5):584-585.

doi: 10.1093/neuonc/noy034.

¹ Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

No abstract available

Comment on

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP. Chinnaiyan P, et al. Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209. Neuro Oncol. 2018. PMID: 29126203 Free PMC article. Clinical Trial.

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361(9354):323–331. - PubMed
1. The Cancer Genome Atlas (TCGA) GBM Project. Available at https://portal.gdc.cancer.gov/projects/TCGA-GBM. Accessed on February 15, 2018.
1. Kim DH, Sarbassov DD, Ali SM et al. . mTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163–175. - PubMed
1. Sarbassov DD, Ali SM, Kim DH et al. . Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–1302. - PubMed
1. Rich JN, Hans C, Jones B et al. . Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005;65(10):4051–4058. - PubMed